SCHEMBL20535348

SCHEMBL20535348

COC(=O)/C(=C/c1cccc(Cl)c1Oc1ccccc1)N=[N+]=[N-]

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.35
▸ POLB P06746 2/20 0.35
▸ HDAC1 Q13547 1/20 0.35
▸ HDAC8 Q9BY41 1/20 0.35
▸ HDAC6 Q9UBN7 1/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ ALDH1A1 P00352 3/20 0.34
▸ HPGD P15428 2/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ RAF1 P04049 1/20 0.33
▸ GAA P10253 1/20 0.33
▸ LMNA P02545 4/20 0.33
▸ STK39 Q9UEW8 1/20 0.33
▸ FABP3 P05413 1/20 0.32
▸ FABP4 P15090 1/20 0.32
▸ TDP1 Q9NUW8 1/20 0.32
▸ L3MBTL1 Q9Y468 1/20 0.32
▸ NPC1 O15118 1/20 0.32
▸ HTT P42858 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20535345 1.00 MAPT (0.35) MAPTPOLBHDAC1HDAC8HDAC6
SCHEMBL20536427 0.88 SMN1; SMN2 (0.32) MAPTPOLBHPGDSMN1; SMN2STK39
SCHEMBL20536428 0.88 SMN1; SMN2 (0.32) MAPTPOLBHPGDSMN1; SMN2STK39
SCHEMBL29015363 0.87 KDM4E (0.35) MAPTHDAC1HDAC8HDAC6KMT2A
SCHEMBL25762543 0.87 KDM4E (0.35) MAPTHDAC1HDAC8HDAC6KMT2A
SCHEMBL30008449 0.87 KDM4E (0.35) MAPTHDAC1HDAC8HDAC6KMT2A
SCHEMBL19343560 0.84 MAPT (0.40) MAPTPOLBHDAC1HDAC8HDAC6
SCHEMBL29015396 0.82 HTT (0.45) MAPTPOLBKMT2AMEN1ALDH1A1
SCHEMBL24189544 0.82 SMN1; SMN2 (0.37) POLBHDAC1HDAC8HDAC6ALDH1A1
SCHEMBL20536246 0.82 SMN1; SMN2 (0.37) POLBHDAC1HDAC8HDAC6ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11339144-B2 Heteroaryl Rheb inhibitors and uses thereof NAVITOR PHARMACEUTICALS, INC. (US) 2022-05-24 — — US disclosed
US-11339144-B2 Heteroaryl Rheb inhibitors and uses thereof NAVITOR PHARMACEUTICALS, INC. (US) 2022-05-24 — — US disclosed
US-20210238165-A1 HETEROARYL RHEB INHIBITORS AND USES THEREOF NAVITOR PHARMACEUTICALS, INC. 2021-08-05 — — US disclosed
US-20210238165-A1 HETEROARYL RHEB INHIBITORS AND USES THEREOF NAVITOR PHARMACEUTICALS, INC. 2021-08-05 — — US disclosed
WO-2018191146-A1 HETEROARYL RHEB INHIBITORS AND USES THEREOF NAVITOR PHARMACEUTICALS, INC. (US) 2018-10-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210238165-A1 HETEROARYL RHEB INHIBITORS AND USES THEREOF RHEB, KRAS, NRAS MAPT 4119/4885POLB 286/4885HDAC1 1729/4885
US-11339144-B2 Heteroaryl Rheb inhibitors and uses thereof RHEB, GDI2, KRAS MAPT 2840/4885POLB 178/4885HDAC1 1588/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback